CFT8634

Overview

CFT8634 is an orally active BRD9 PROTAC degrader with a DC 50 of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN -catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1 -deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma. (Pink: BRD9 ligand ( HY-169988 ); Blue: Cereblon ligand ( HY-169989 ); Black: linker ( HY-169991 )).

Application

Products | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Epigenetic Reader Domain

Product Information

• Catalog No.: HY-145925B
• CAS No.: 2704617-96-7
• Molecular Formula: C37H45F3N6O5
• Molecular Weight: 710.79
• Purity: 98.10%
• Storage: 4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (3.52 mM); Clear solution
• Availability: In-stock

Source

Original product source